Azenta (AZTA) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue rose 4%–5% year-over-year to $173 million, with organic growth driven by Sample Management Solutions and B Medical Systems, while Multiomics remained flat.

• Adjusted EBITDA margin expanded to 10.3%, up 260 basis points year-over-year and 440 basis points sequentially, with non-GAAP EPS at $0.16.

• Transformation initiatives under Ascend 2026 and ongoing restructuring are delivering cost savings, operational efficiencies, and margin expansion.

• CEO search is ongoing, with strong interest from qualified candidates.

• Net loss for Q3 2024 was $6.6 million, primarily due to lower interest income and significant non-cash impairment charges in the nine-month period.

Financial highlights

• Q3 revenue reached $173 million, up 5% organically and 9% sequentially; gross margin was 40% GAAP and 45.2% non-GAAP.

• Adjusted EBITDA margin was 10.3%; non-GAAP operating margin was 2.6%, up 330 basis points year-over-year.

• Non-GAAP EPS was $0.16; GAAP diluted EPS from continuing operations was ($0.12).

• Cash, cash equivalents, and marketable securities totaled $754 million at quarter end, with no debt outstanding.

• Returned $225.9 million to shareholders via repurchase of 4.2 million shares in Q3; $1.25 billion repurchased under 2022 authorization.

Outlook and guidance

• FY24 revenue guidance lowered to $652–$658 million, or down 2% to down 1% year-over-year, due to B Medical conversion delays and OEM order shifts.

• Adjusted EBITDA margin expansion of ~300 basis points reaffirmed; non-GAAP EPS guidance raised to $0.30–$0.36.

• Interest income for FY24 expected to be ~$32 million; tax rate expected at 30%–34%.

• Management expects current liquidity to fund operations and capital needs for at least one year and the foreseeable future.